Pharmacies

Help patients get started on treatment

Photos not of actual patients

Have a patient
starting treatment?

Support Path is here to help.

Get your patients started today through the resources below, or call 1-855-7-MYPATH (1-855-769-7284) to connect live with a Program Navigator.

Resources to help patients access and start therapy

Co-pay coupon

Cost should not be a barrier to treatment. Register patients for a co-pay coupon

The co-pay coupon may help eligible commercially-insured patients reduce out-of-pocket costs of Gilead or Asegua treatment.

  • The co-pay coupon is not insurance and is not intended to substitute for insurance. The co-pay coupon is valid only for patients with commercial insurance and is not valid for prescriptions that are eligible to be reimbursed:
    • in whole or in part by Medicare or a Medicare Part D plan, Medicaid, TRICARE, VA, DOD, Puerto Rico Government Health Insurance Plan, or any other state or federally funded healthcare benefit program (collectively, “Government Programs”); or
    • by commercial plans or other health or pharmacy benefit programs that reimburse for the entire cost of prescription drugs or prohibit the co-pay coupon's use.
  • Medicare Part D enrollees who are in the prescription drug coverage gap (the “donut hole”) are not eligible for the co-pay coupon. Patients who begin receiving prescription benefits from Government Programs at any time will no longer be eligible to use the co-pay coupon.
    Additional restrictions may apply. For full terms and conditions, visit the corresponding product’s website (linked below).

Click below to register and read full terms and conditions:

Co-pay coupon
EPCLUSA® (sofosbuvir 400 mg/velpatasvir 100 mg) tablets
HARVONI® (ledipasvir 90 mg/sofosbuvir 400 mg) tablets
VOSEVI® (sofosbuvir 400 mg/velpatasvir 100 mg/voxilaprevir 100 mg) tablets
SOVALDI® (sofosbuvir 400 mg) tablets
Authorized Generic of EPCLUSA® (sofosbuvir 400 mg/velpatasvir 100 mg) tablets
Authorized Generic of HARVONI® (ledipasvir 90 mg/sofosbuvir 400 mg) tablets
VEMLIDY (tenofovir alafenamide 25 mg) tablets

Please see full Prescribing Information for EPCLUSA, HARVONI, VOSEVI, SOVALDI, sofosbuvir/velpatasvir, ledipasvir/sofosbuvir, and VEMLIDY, including BOXED WARNING.

Support Path Enrollment Form

Direct Patients to Submit a Support Path Enrollment Form

Support Path can help patients understand insurance coverage and financial support options to get started. Use the Support Path Enrollment Form to select from the following support options:

  • Benefits investigation
  • Prior Authorization and appeals information
  • Patient Assistance Program (PAP) eligibility screening
Please see full Prescribing Information for EPCLUSA, HARVONI, VOSEVI, SOVALDI, sofosbuvir/velpatasvir, ledipasvir/sofosbuvir, and VEMLIDY, including BOXED WARNING.
Gilead corporate logo Asegua logo

Photos not of actual patients.
EPCLUSA, the EPCLUSA logo, HARVONI, the HARVONI logo, SOVALDI, the SOVALDI logo, VEMLIDY, the VEMLIDY logo, VOSEVI, the VOSEVI logo, SUPPORT PATH, the SUPPORT PATH logo, GILEAD and the GILEAD logo are trademarks of Gilead Sciences, Inc., or its related companies. ASEGUA and the ASEGUA logo are trademarks of Asegua Therapeutics LLC. All other trademarks referenced herein are the property of their respective owners.

©2021 Gilead Sciences, Inc. All rights reserved. US-PTFC-0010 12/21